Evidence review of documented associations between vaccines and GBS.
Guillain-Barré Syndrome (GBS) is a rare neurological disorder in which the body's immune system mistakenly attacks the peripheral nervous system. It can cause muscle weakness, paralysis, and in severe cases, respiratory failure requiring mechanical ventilation.
GBS can be triggered by infections — most commonly Campylobacter jejuni (a bacterial gut infection), influenza, cytomegalovirus, and Epstein-Barr virus. A small but documented association between GBS and certain vaccines has been identified and is actively monitored by vaccine safety systems worldwide.
The strongest documented vaccine-GBS association occurred following the 1976 U.S. swine influenza vaccination campaign. Risk was estimated at approximately 1 additional GBS case per 100,000 vaccinated people. The campaign was halted after this signal was detected.
Subsequent seasonal influenza vaccines have shown a much smaller GBS signal — approximately 1–2 additional cases per million doses. This risk is considered substantially lower than the GBS risk associated with influenza infection itself.
A small GBS signal was identified following the Janssen (Johnson & Johnson) adenoviral vector COVID-19 vaccine — approximately 9 cases per million doses within 42 days of vaccination. No significant GBS signal was identified for mRNA COVID-19 vaccines (Pfizer, Moderna).
GBS associations have been investigated for rabies, meningococcal, and hepatitis B vaccines. Evidence for a causal relationship remains inconclusive for most of these.
A critical context consideration:
Influenza infection itself is associated with a substantially higher GBS risk than influenza vaccination. Studies estimate influenza infection carries a GBS risk of approximately 17 cases per million infections — compared to 1–2 cases per million influenza vaccine doses.
This means for most people, the GBS risk from declining vaccination (and therefore increasing infection risk) exceeds the GBS risk from the vaccine itself.
GBS typically presents 2–4 weeks after a triggering event (infection or vaccination). Key symptoms:
Diagnosis is confirmed by lumbar puncture (showing elevated protein in CSF) and nerve conduction studies. Most patients recover fully within 6–12 months, though recovery can be prolonged.
All cases of GBS following vaccination must be reported to VAERS. GBS is a VAERS Table Injury for some vaccines, meaning it triggers automatic compensation review under VICP.
Both the CDC's Vaccine Safety Datalink and the FDA's BEST program actively monitor GBS rates in vaccinated populations, allowing calculation of true incidence rates and comparison to baseline.
The Brighton Collaboration maintains standardised case definitions for GBS to ensure consistent diagnosis and reporting across international vaccine safety studies.